Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk Disease | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk Disease	Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, mantle cell lymphoma, neoplasm	Recruiting	Phase 2	2026-07-28		NCT07272499

11 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
First Affiliated Hospital of Wenzhou Medical University	117
Fujian Medical University Union Hospital	108
Jiujiang No.1 People's Hospital	9
Qilu Hospital of Shandong University	249
Ruijin Hospital	454
Shanghai 411 hospital	2
Shanghai Minhang Central Hospital	10
The First Affiliated Hospital of Anhui Medical University	85
The Third Xiangya Hospital of Central South University	75
Xuhui Central Hospital, Shanghai	9
Yangpu District Central Hospital Affiliated to Tongji University	3

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine	Shanghai	China	27